Holen Sie sich die Stockscreener-App
49.97
2.12%
-1.08
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$51.05
Offen:
$50.32
24-Stunden-Volumen:
2.79M
Relative Volume:
0.51
Marktkapitalisierung:
$13.19B
Einnahmen:
$14.00B
Nettoeinkommen (Verlust:
$1.26B
KGV:
10.25
EPS:
4.8749
Netto-Cashflow:
$352.00M
1W Leistung:
-0.70%
1M Leistung:
+6.71%
6M Leistung:
-18.81%
1J Leistung:
+59.70%
1-Tages-Spanne:
$49.86
$50.72
1-Wochen-Bereich:
$49.07
$52.58
52-Wochen-Spanne:
$30.71
$84.38
Agilent Technologies Inc Stock (AA) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
412-315-2900
Adresse
201 ISABELLA STREET, PITTSBURGH, PA
Compare AA vs TMO, DHR, NTRA, IQV, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AA
Agilent Technologies Inc
|
49.97 | 13.34B | 14.00B | 1.26B | 352.00M | 4.8749 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Agilent Technologies Inc Stock (AA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2026-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-01-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-08 | Fortgesetzt | Citigroup | Buy |
| 2025-05-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-08 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-10-23 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-10-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-09-25 | Fortgesetzt | JP Morgan | Neutral |
| 2024-09-04 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-08-12 | Hochstufung | UBS | Sell → Buy |
| 2024-08-02 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-06-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-04-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-01-16 | Eingeleitet | UBS | Sell |
| 2023-12-07 | Eingeleitet | HSBC Securities | Hold |
| 2023-10-23 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-24 | Herabstufung | Argus | Buy → Hold |
| 2023-07-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-07-11 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-06-22 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-05-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-05-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-02-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-01-19 | Bestätigt | B. Riley Securities | Neutral |
| 2022-12-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-07 | Eingeleitet | UBS | Neutral |
| 2022-09-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-09-16 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-08 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-11-17 | Eingeleitet | Wolfe Research | Outperform |
| 2021-11-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-10-05 | Bestätigt | JP Morgan | Overweight |
| 2021-09-29 | Bestätigt | Morgan Stanley | Overweight |
| 2021-09-15 | Hochstufung | Argus | Hold → Buy |
| 2021-07-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-23 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-03-03 | Hochstufung | Goldman | Sell → Buy |
| 2020-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2020-03-24 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-03-04 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2020-01-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2019-12-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-11-13 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-21 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-09-26 | Bestätigt | B. Riley FBR | Buy |
| 2019-09-23 | Herabstufung | Goldman | Buy → Neutral |
| 2019-09-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-08-16 | Bestätigt | BofA/Merrill | Neutral |
| 2019-07-19 | Herabstufung | Argus | Buy → Hold |
| 2019-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-07-09 | Herabstufung | Macquarie | Outperform → Neutral |
| 2019-04-22 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-04-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-04-02 | Herabstufung | Credit Suisse | Outperform → Neutral |
Alle ansehen
Agilent Technologies Inc Aktie (AA) Neueste Nachrichten
Price to sales forward of Agilent Technologies, Inc. – MIL:1A - TradingView
Agilent Technologies stock gains as FDA-cleared S540MD slide scanner strengthens digital pathology p - AD HOC NEWS
Agilent Technologies | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Mikael Dolsten to sell Agilent (NYSE: A) stock - stocktitan.net
Worker says Agilent fired him to mask race and age bias - hcamag.com
Agilent Technologies stock gains on digital pathology launch and strong Q3 figures - AD HOC NEWS
Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System - 01net
Agilent Technologies Launches FDA-Cleared S540MD Slide Scanner in US - marketscreener.com
Agilent launches FDA-cleared slide scanner in U.S. market By Investing.com - Investing.com Australia
Baird Adjusts Price Target on Agilent Technologies to $180 From $169, Keeps Outperform Rating - marketscreener.com
Agilent Technologies Inc (A) Looks 2.6% Overvalued on GF Value™ - GuruFocus
Agilent: The Recovery Is Real, But So Is The Valuation (NYSE:A) - Seeking Alpha
A SWOT Analysis: Agilent Technologies Inc (A) Reveals Financial Insights in 10-Q Filing - GuruFocus
Bond swap: Agilent (NYSE: A) offers to exchange $600M in 4.9% notes - stocktitan.net
Agilent (NYSE: A) readies global debt program with $100M default triggers - stocktitan.net
Agilent Technologies 3Q 2026: Revenue $1.88B, EPS $1.28— 10-Q Summary - TradingView
Agilent (NYSE: A) spends $950M on Biocare — see how Q3 earnings and debt shifted - stocktitan.net
Agilent Introduces the Cary 635 FTIR Spectrometer - Yahoo Finance
Agilent Technologies, Inc. Introduces The Cary 635 FTIR Spectrometer - marketscreener.com
Agilent launches Cary 635 FTIR spectrometer for laboratories - Investing.com
HSBC Adjusts Price Target on Agilent Technologies to $175 From $165, Maintains Buy Rating - marketscreener.com
AGILENT TECHNOLOGIES INC : HSBC RAISES TARGET PRICE TO $175 FROM $165 - Bitget
International Markets and Agilent (A): A Deep Dive for Investors - Yahoo Finance
Weekly Recap: Agilent (A) Q3 results and pharma reshoring opportunity - TradingView
Stronger Q3 Results and Raised Guidance Could Be A Game Changer For Agilent Technologies (A) - Sahm
Agilent Technologies Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wells Fargo Adjusts Price Target on Agilent Technologies to $180 From $160, Keeps Overweight Rating - Moomoo
Agilent (NYSE) Expanded Non-GAAP Margin 320 bps. How Much Is Repeatable? - Yahoo Finance
Rothschild & Co Redburn Adjusts Agilent Technologies Price Target to $180 From $160, Maintains Buy Rating - Moomoo
Agilent Technologies: Q3 Growth, Expanding Margins, And Raised Guidance - Seeking Alpha
Agilent Technologies beats estimates, raises guidance on strong demand; shares up - Investing.com
AGILENT TECHNOLOGIES INC : RBC RAISES TARGET PRICE TO $185 FROM $155 - Bitget
Agilent Technologies Q3 Earnings Call Highlights - Yahoo Finance
Transcript : Agilent Technologies, Inc., Q3 2026 Earnings Call, Aug 26, 2026 - marketscreener.com
Is Agilent Technologies Inc (A) Overvalued After Q3 Earnings? EP - GuruFocus
Agilent: Fiscal Q3 Earnings Snapshot - 10TV
Agilent Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026 - marketscreener.com
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results - Business Wire
Agilent Technologies (A) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Agilent Technologies Slides Ahead of Earnings as Investors Appear Cautious - Moomoo
Agilent Technologies Inc. Stock Slips 3.5%, Underperforms Peers - Bitget
Why Agilent Technologies (A) Is Up 7.0% After Q2 Beat And Higher 2026 GuidanceAnd What's Next - simplywall.st
Agilent Technologies stock hits 52-week high at 160.36 USD - Investing.com
Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore - 24/7 Wall St.
Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS - Yahoo Finance
Agilent Technologies (A) Q3 2026 Preview: EPS Est. $1.44, Reports August 26 - AlphaStreet
Agilent Technologies stock trades close to 12?month high as guidance and analyst consensus support o - Ad-hoc-news.de
Agilent Technologies stock gains after fresh analyst target lift and regulatory filing - Ad-hoc-news.de
A5143230 Bond Profile — Key Metrics - TradingView
What Are Wall Street Analysts' Target Price for Agilent Technologies Stock? - inkl
Agilent Technologies (A) Gains Attention In Cannabis Testing, Is It Fully Valued? - simplywall.st
Finanzdaten der Agilent Technologies Inc-Aktie (AA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):